Oxford Gene Technology (OGT)

OGT delivers superior MRD detection capabilities with new SureSeq Myeloid MRD Panel

22 January 2025 – New York City, NY, US – Today, OGT announces the North American launch of its new next-generation sequencing (NGS) SureSeq™ Myeloid MRD Panel, which provides a flexible NGS workflow for the detection of ultra-low frequency measurable residual disease (MRD)-associated biomarkers in acute myeloid leukemia (AML). This ultra-sensitive NGS panel leverages OGT’s...

Leading experts reveal how exon-focused microarrays are advancing genetic syndrome research

Oxford, UK - 14 July 2016. Oxford Gene Technology (OGT), The Molecular Genetics Company, held an exclusive workshop exploring the power of exon-focused microarrays in enhancing genetic syndrome research at the recent European Human Genetics Conference (ESHG). Three expert clinical researchers from across the globe shared their knowledge of enhanced CNV detection with OGTís CytoSure™...

OGT enhances NGS results from FFPE samples

Molecular Genetics Company introduces product designed to repair damage to DNA
Begbroke Science Park, Begbroke Hill, Woodstock Road, Begbroke, Oxfordshire, OX5 1PF, UK

+44 (0)1865 856800